

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

AN ACT

RELATING TO PROFESSIONAL LICENSURE; AMENDING AND REPEALING
SECTIONS OF THE OPTOMETRY ACT TO MAKE CHANGES TO BOARD POWERS
AND TO PROVIDE OPTOMETRISTS WITH GREATER PRESCRIBING POWERS;
AMENDING A SECTION OF THE NEW MEXICO DRUG, DEVICE AND
COSMETIC ACT TO INCLUDE OPTOMETRISTS AS PRESCRIBING
PRACTITIONERS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. Section 61-2-2 NMSA 1978 (being Laws 1973,
Chapter 353, Section 2, as amended) is amended to read:

"61-2-2. DEFINITIONS.--As used in the Optometry Act:

A. "practice of optometry" means:

(1) the employment of any subjective or
objective means or methods, including but not limited to the
use of lenses, prisms, autorefractors or other automated
testing devices, and includes the prescription or
administration of drugs for the purpose of diagnosing the
visual defects or abnormal conditions of the human eye and
its adnexa;

(2) the employing, adapting or prescribing
of preventive or corrective measures, including but not
limited to lenses, prisms, contact or corneal lenses or other
optical appliances, ocular exercises, vision therapy, vision
training and vision rehabilitation services, and includes the

1 prescription or administration of all drugs rational for the
2 correction, relief or referral of visual defects or abnormal
3 conditions of the human eye and its adnexa; and

4 (3) does not include the use of surgery or
5 injections in the treatment of eye diseases except for the
6 use of the following types of in-office minor surgical
7 procedures:

8 (a) non-laser removal, destruction or
9 drainage of superficial eyelid lesions and conjunctival
10 cysts;

11 (b) removal of nonperforating foreign
12 bodies from the cornea, conjunctiva and eyelid;

13 (c) non-laser corneal debridement,
14 culture, scrape or anterior puncture, not including removal
15 of pterygium, corneal biopsy or removal of corneal
16 neoplasias;

17 (d) removal of eyelashes; and

18 (e) probing, dilation, irrigation or
19 closure of the tear drainage structures of the eyelid;
20 scalpel use is to be applied only for the purpose of use on
21 the skin surrounding the eye;

22 B. "ophthalmic lens" means a lens that has a
23 spherical, cylindrical or prismatic value, is ground pursuant
24 to a prescription and is intended to be used as eyeglasses;

25 C. "contact lens" means a lens to be worn on the

1 anterior segment of the human eye;

2 D. "prescription" means a written order by an
3 optometrist or a physician for an individual patient for:

4 (1) ophthalmic lenses;

5 (2) contact lenses; or

6 (3) a pharmaceutical agent that is regulated
7 pursuant to the New Mexico Drug, Device and Cosmetic Act;

8 E. "eyeglasses" means an exterior optical device
9 using ophthalmic lenses for the correction or relief of
10 disturbances in and anomalies of human vision; and

11 F. "board" means the board of optometry."

12 SECTION 2. Section 61-2-6 NMSA 1978 (being Laws 1973,
13 Chapter 353, Section 5, as amended) is amended to read:

14 "61-2-6. ORGANIZATION--MEETINGS--COMPENSATION--POWERS
15 AND DUTIES.--

16 A. The board shall annually elect a chair, a
17 vice chair and a secretary-treasurer; each shall serve until
18 a successor is elected and qualified.

19 B. The board shall meet at least annually for the
20 purpose of examining candidates for licensure. Special
21 meetings may be called by the chair and shall be called upon
22 the written request of a majority of the board members. A
23 majority of the board members currently serving constitutes a
24 quorum.

25 C. Members of the board may be reimbursed as

1 provided in the Per Diem and Mileage Act but shall receive no
2 other compensation, perquisite or allowance.

3 D. The board has the authority to determine what
4 constitutes the practice of optometry in accordance with the
5 provisions of the Optometry Act and has jurisdiction to
6 exercise any other powers and duties pursuant to that act.
7 The board may issue advisory opinions and declaratory rulings
8 pursuant to that act and rules promulgated in accordance with
9 that act, but shall not expand the scope of practice of
10 optometry beyond the provisions of that act.

11 E. The board shall:

12 (1) administer and enforce the provisions of
13 the Optometry Act;

14 (2) adopt, publish and file, in accordance
15 with the Uniform Licensing Act and the State Rules Act, all
16 rules for the implementation and enforcement of the
17 provisions of the Optometry Act;

18 (3) adopt and use a seal;

19 (4) administer oaths and take testimony on
20 matters within the board's jurisdiction;

21 (5) keep an accurate record of meetings,
22 receipts and disbursements;

23 (6) keep a record of examinations held,
24 together with the names and addresses of persons taking the
25 examinations and the examination results. Within thirty days

1 after an examination, the board shall give written notice to
2 each applicant examined of the results of the examination as
3 to the respective applicant;

4 (7) certify as passing each applicant who
5 obtains a grade of at least seventy-five percent on each
6 subject upon which the applicant is examined; providing that
7 an applicant failing may apply for re-examination at the next
8 scheduled examination date;

9 (8) keep a book of registration in which the
10 name, address and license number of licensees shall be
11 recorded, together with a record of license renewals,
12 suspensions and revocations;

13 (9) grant, deny, renew, suspend or revoke
14 licenses to practice optometry in accordance with the
15 provisions of the Uniform Licensing Act for any cause stated
16 in the Optometry Act;

17 (10) develop and administer qualifications
18 for certification for the use of pharmaceutical agents as
19 authorized in Section 61-2-10.2 NMSA 1978, including minimum
20 educational requirements and examination, as required by
21 Section 61-2-10.2 NMSA 1978 and provide the board of pharmacy
22 with an annual list of optometrists certified to use
23 pharmaceutical agents as authorized in Section 61-2-10.2
24 NMSA 1978; and

25 (11) provide for the suspension of an

1 optometrist's license for sixty days upon a determination of
2 use of pharmaceutical agents without prior certification in
3 accordance with Section 61-2-10.2 NMSA 1978, after proper
4 notice and an opportunity to be heard before the board."

5 SECTION 3. Section 61-2-10.2 NMSA 1978 (being Laws
6 1995, Chapter 20, Section 5, as amended) is amended to read:

7 "61-2-10.2. DESIGNATION OF PHARMACEUTICAL AGENTS--
8 CERTIFICATION FOR USE OF CERTAIN AGENTS.--

9 A. Subject to the provisions of the Optometry Act,
10 optometrists qualified and certified by the board may
11 prescribe or administer all pharmaceutical agents for the
12 diagnosis and treatment of disease of the eye or adnexa;
13 provided that an optometrist:

14 (1) may prescribe hydrocodone and
15 hydrocodone combination medications;

16 (2) may administer epinephrine
17 auto-injections to counter anaphylaxis; and

18 (3) shall not prescribe any other controlled
19 substance classified in Schedule I or II pursuant to the
20 Controlled Substances Act.

21 B. The board shall issue certification for the use
22 of pharmaceutical agents as set forth in Subsection A of this
23 section to optometrists currently licensed by the board. To
24 be certified, an optometrist shall submit to the board proof
25 of having satisfactorily completed a course in pharmacology

1 as applied to optometry, with particular emphasis on the
2 administration of pharmaceutical agents for the purpose of
3 examination of the human eye, and analysis of ocular
4 functions and treatment of visual defects or abnormal
5 conditions of the human eye and its adnexa. The course shall
6 constitute a minimum of twenty hours of instruction in
7 clinical pharmacology, including systemic pharmacology as
8 applied to optometry, and shall be taught by an accredited
9 institution approved by the board.

10 C. Applicants for licensure shall meet the
11 requirements for certification in the use of pharmaceutical
12 agents as set forth in the Optometry Act and shall
13 successfully complete the board's examination in
14 pharmaceutical agents prior to licensure.

15 D. The certification authorized by this section
16 shall be displayed in a conspicuous place in the
17 optometrist's principal office or place of business."

18 SECTION 4. Section 61-2-10.3 NMSA 1978 (being Laws
19 2003, Chapter 274, Section 8) is amended to read:

20 "61-2-10.3. PRESCRIPTION FOR PHARMACEUTICAL AGENT OR
21 OPHTHALMIC LENSES--REQUIRED ELEMENTS--AUTHORITY OF A PERSON
22 WHO SELLS AND DISPENSES EYEGLASSES.--

23 A. A prescription written for a pharmaceutical
24 agent shall include an order given individually for the
25 person for whom prescribed, either directly from the

1 prescriber to a pharmacist or indirectly by means of a
2 written or electronic order signed by the prescriber, that
3 bears the name and address of the prescriber, the
4 prescriber's license classification, the name and address of
5 the patient, the name and quantity of the agent prescribed
6 and directions for its use and the date of issue.

7 B. A prescription written for ophthalmic lenses
8 shall include:

9 (1) the dioptric power of spheres, cylinders
10 and prisms, the axes of cylinders, the position of the prism
11 base and, if so desired by the prescriber, the light
12 transmission properties and lens curve values;

13 (2) the designation of pupillary distance;
14 and

15 (3) the name of the patient, the date of the
16 prescription, the expiration date of the prescription and the
17 name and address of the prescriber.

18 C. A person who sells and dispenses eyeglasses
19 upon the written prescription of a physician, surgeon or
20 optometrist may determine:

21 (1) the type, form, size and shape of
22 ophthalmic lenses;

23 (2) the placement of optical centers for
24 distance-seeing and near-work;

25 (3) the designation of type and placement of

1 reading segments in multivision lenses;

2 (4) the type and quality of frame or
3 mounting, the type of bridge and the distance between lenses
4 and the type, length and angling of temples; and

5 (5) the designation of pupillary distance."

6 SECTION 5. Section 61-2-14 NMSA 1978 (being Laws 1973,
7 Chapter 353, Section 12, as amended) is amended to read:

8 "61-2-14. OFFENSES.--

9 A. A person who commits one of the following acts
10 is guilty of a fourth degree felony and upon conviction shall
11 be sentenced pursuant to the provisions of Section 31-18-15
12 NMSA 1978:

13 (1) practicing or attempting to practice
14 optometry without a valid current license issued by the
15 board;

16 (2) using or attempting to use a
17 pharmaceutical agent that is regulated pursuant to the
18 provisions of the New Mexico Drug, Device and Cosmetic Act
19 without having the certification for its use issued by the
20 board, unless the administration of pharmaceutical agents is
21 done under the direct supervision of a licensed optometrist
22 certified to administer the pharmaceutical agents in
23 accordance with the provisions of the Optometry Act; or

24 (3) permitting a person in one's employ,
25 supervision or control to practice optometry or use

1 pharmaceutical agents described in Paragraph (2) of this
2 subsection unless that person is licensed and certified in
3 accordance with the provisions of the Optometry Act or unless
4 the administration of pharmaceutical agents is done under the
5 direct supervision of a licensed optometrist certified to
6 administer the pharmaceutical agents in accordance with the
7 provisions of the Optometry Act.

8 B. A person who commits one of the following acts
9 is guilty of a misdemeanor and upon conviction shall be
10 sentenced pursuant to the provisions of Section 31-19-1
11 NMSA 1978:

12 (1) making a willfully false oath or
13 affirmation where the oath or affirmation is required by the
14 Optometry Act;

15 (2) selling or using any designation,
16 diploma or certificate tending to imply that one is a
17 practitioner of optometry, unless one holds a license as
18 provided by the Optometry Act;

19 (3) refusing, after a request, to provide a
20 patient a copy of the patient's eyeglasses prescription, if
21 the prescription is not over one year old;

22 (4) duplicating or replacing an ophthalmic
23 lens without a current prescription not more than two years
24 old or without a written authorization from the patient if
25 the prescription is not available;

1 (5) except for licensed optometrists, using
2 any trial lenses, trial frames, graduated test cards or other
3 appliances or instruments for the purpose of examining the
4 eyes or rendering assistance to anyone who desires to have an
5 examination of the eyes, but it is not the intent of this
6 paragraph to prevent a school nurse, schoolteacher or
7 employee in public service from ascertaining the possible
8 need of vision services, if the person, clinic or program
9 does not attempt to diagnose or prescribe ophthalmic lenses
10 for the eyes or recommend any particular practitioner or
11 system of practice;

12 (6) advertising the fabricating, adapting,
13 employing, providing, sale or duplication of eyeglasses or
14 any part of them, but this paragraph does not preclude the
15 use of a business name, trade name or trademark not relating
16 to price or the use of the address, telephone number, office
17 hours and designation of the provider, in or at retail
18 outlets, on business cards, eyeglass cleaners and cases or in
19 news media or in public directories, mailings and
20 announcements of location openings or the use of the words
21 "doctors' prescriptions for eyeglasses filled" or "eyeglass
22 repairs, replacements and adjustments"; or

23 (7) selling of prescription eyeglasses or
24 contact lenses, frames or mountings for lenses in an
25 establishment in which the majority of its income is not

1 derived from being engaged in that endeavor."

2 SECTION 6. Section 26-1-2 NMSA 1978 (being Laws 1967,
3 Chapter 23, Section 2, as amended) is amended to read:

4 "26-1-2. DEFINITIONS.--As used in the New Mexico Drug,
5 Device and Cosmetic Act:

6 A. "board" means the board of pharmacy or its duly
7 authorized agent;

8 B. "person" includes an individual, partnership,
9 corporation, association, institution or establishment;

10 C. "biological product" means a virus, therapeutic
11 serum, toxin, antitoxin or analogous product applicable to
12 the prevention, treatment or cure of diseases or injuries of
13 humans and domestic animals, and, as used within the meaning
14 of this definition:

15 (1) a "virus" is interpreted to be a product
16 containing the minute living cause of an infectious disease
17 and includes filterable viruses, bacteria, rickettsia, fungi
18 and protozoa;

19 (2) a "therapeutic serum" is a product
20 obtained from blood by removing the clot or clot components
21 and the blood cells;

22 (3) a "toxin" is a product containing a
23 soluble substance poisonous to laboratory animals or humans
24 in doses of one milliliter or less of the product and,
25 following the injection of nonfatal doses into an animal,

1 having the property of or causing to be produced therein
2 another soluble substance that specifically neutralizes the
3 poisonous substance and that is demonstrable in the serum of
4 the animal thus immunized; and

5 (4) an "antitoxin" is a product containing
6 the soluble substance in serum or other body fluid of an
7 immunized animal that specifically neutralizes the toxin
8 against which the animal is immune;

9 D. "controlled substance" means a drug, substance
10 or immediate precursor enumerated in Schedules I through V of
11 the Controlled Substances Act;

12 E. "drug" means articles:

13 (1) recognized in an official compendium;

14 (2) intended for use in the diagnosis, cure,
15 mitigation, treatment or prevention of disease in humans or
16 other animals and includes the domestic animal biological
17 products regulated under the federal Virus-Serum-Toxin Act,
18 37 Stat 832-833, 21 U.S.C. 151-158, and the biological
19 products applicable to humans regulated under Federal 58
20 Stat 690, as amended, 42 U.S.C. 216, Section 351, 58 Stat
21 702, as amended, and 42 U.S.C. 262;

22 (3) other than food, that affect the
23 structure or any function of the human body or the bodies of
24 other animals; and

25 (4) intended for use as a component of

1 Paragraph (1), (2) or (3) of this subsection, but "drug" does
2 not include devices or their component parts or accessories;

3 F. "dangerous drug" means a drug, other than a
4 controlled substance enumerated in Schedule I of the
5 Controlled Substances Act, that because of a potentiality for
6 harmful effect or the method of its use or the collateral
7 measures necessary to its use is not safe except under the
8 supervision of a practitioner licensed by law to direct the
9 use of such drug and hence for which adequate directions for
10 use cannot be prepared. "Adequate directions for use" means
11 directions under which the layperson can use a drug or device
12 safely and for the purposes for which it is intended. A drug
13 shall be dispensed only upon the prescription or drug order
14 of a practitioner licensed by law to administer or prescribe
15 the drug if it:

16 (1) is a habit-forming drug and contains any
17 quantity of a narcotic or hypnotic substance or a chemical
18 derivative of such substance that has been found under the
19 federal act and the board to be habit forming;

20 (2) because of its toxicity or other
21 potential for harmful effect or the method of its use or the
22 collateral measures necessary to its use is not safe for use
23 except under the supervision of a practitioner licensed by
24 law to administer or prescribe the drug;

25 (3) is limited by an approved application by

1 Section 505 of the federal act to the use under the
2 professional supervision of a practitioner licensed by law to
3 administer or prescribe the drug;

4 (4) bears the legend: "Caution: federal
5 law prohibits dispensing without prescription.";

6 (5) bears the legend: "Caution: federal
7 law restricts this drug to use by or on the order of a
8 licensed veterinarian."; or

9 (6) bears the legend "RX only";

10 G. "counterfeit drug" means a drug that is
11 deliberately and fraudulently mislabeled with respect to its
12 identity, ingredients or sources. Types of such
13 pharmaceutical counterfeits may include:

14 (1) "identical copies", which are
15 counterfeits made with the same ingredients, formulas and
16 packaging as the originals but not made by the original
17 manufacturer;

18 (2) "look-alikes", which are products that
19 feature high-quality packaging and convincing appearances but
20 contain little or no active ingredients and may contain
21 harmful substances;

22 (3) "rejects", which are drugs that have
23 been rejected by the manufacturer for not meeting quality
24 standards; and

25 (4) "relabels", which are drugs that have

1 passed their expiration dates or have been distributed by
2 unauthorized foreign sources and may include placebos created
3 for late-phase clinical trials;

4 H. "device", except when used in Subsection P of
5 this section and in Subsection G of Section 26-1-3,
6 Subsection L and Paragraph (4) of Subsection A of
7 Section 26-1-11 and Subsection C of Section 26-1-24
8 NMSA 1978, means an instrument, apparatus, implement,
9 machine, contrivance, implant, in vitro reagent or other
10 similar or related article, including any component, part or
11 accessory, that is:

12 (1) recognized in an official compendium;

13 (2) intended for use in the diagnosis of
14 disease or other conditions or in the cure, mitigation,
15 treatment or prevention of disease in humans or other
16 animals; or

17 (3) intended to affect the structure or a
18 function of the human body or the bodies of other animals and
19 that does not achieve any of its principal intended purposes
20 through chemical action within or on the human body or the
21 bodies of other animals and that is not dependent on being
22 metabolized for achievement of any of its principal intended
23 purposes;

24 I. "prescription" means an order given
25 individually for the person for whom prescribed, either

1 directly from a licensed practitioner or the practitioner's
2 agent to the pharmacist, including by means of electronic
3 transmission, or indirectly by means of a written order
4 signed by the prescriber, and bearing the name and address of
5 the prescriber, the prescriber's license classification, the
6 name and address of the patient, the name and quantity of the
7 drug prescribed, directions for use and the date of issue;

8 J. "practitioner" means a certified advanced
9 practice chiropractic physician, physician, doctor of
10 oriental medicine, dentist, veterinarian, euthanasia
11 technician, certified nurse practitioner, clinical nurse
12 specialist, pharmacist, pharmacist clinician, certified
13 nurse-midwife, physician assistant, prescribing psychologist,
14 dental hygienist, optometrist or other person licensed or
15 certified to prescribe and administer drugs that are subject
16 to the New Mexico Drug, Device and Cosmetic Act;

17 K. "cosmetic" means:

18 (1) articles intended to be rubbed, poured,
19 sprinkled or sprayed on, introduced into or otherwise applied
20 to the human body or any part thereof for cleansing,
21 beautifying, promoting attractiveness or altering the
22 appearance; and

23 (2) articles intended for use as a component
24 of any articles enumerated in Paragraph (1) of this
25 subsection, except that the term shall not include soap;

1 L. "official compendium" means the official United
2 States pharmacopoeia national formulary or the official
3 homeopathic pharmacopoeia of the United States or any
4 supplement to either of them;

5 M. "label" means a display of written, printed or
6 graphic matter upon the immediate container of an article. A
7 requirement made by or under the authority of the New Mexico
8 Drug, Device and Cosmetic Act that any word, statement or
9 other information appear on the label shall not be considered
10 to be complied with unless the word, statement or other
11 information also appears on the outside container or wrapper,
12 if any, of the retail package of the article or is easily
13 legible through the outside container or wrapper;

14 N. "immediate container" does not include package
15 liners;

16 O. "labeling" means all labels and other written,
17 printed or graphic matter:

18 (1) on an article or its containers or
19 wrappers; or

20 (2) accompanying an article;

21 P. "misbranded" means a label to an article that
22 is misleading. In determining whether the label is
23 misleading, there shall be taken into account, among other
24 things, not only representations made or suggested by
25 statement, word, design, device or any combination of the

1 foregoing, but also the extent to which the label fails to
2 reveal facts material in the light of such representations or
3 material with respect to consequences that may result from
4 the use of the article to which the label relates under the
5 conditions of use prescribed in the label or under such
6 conditions of use as are customary or usual;

7 Q. "advertisement" means all representations
8 disseminated in any manner or by any means, other than by
9 labeling, for the purpose of inducing, or that are likely to
10 induce, directly or indirectly, the purchase of drugs,
11 devices or cosmetics;

12 R. "antiseptic", when used in the labeling or
13 advertisement of an antiseptic, shall be considered to be a
14 representation that it is a germicide, except in the case of
15 a drug purporting to be or represented as an antiseptic for
16 inhibitory use as a wet dressing, ointment, dusting powder or
17 such other use as involves prolonged contact with the body;

18 S. "new drug" means a drug:

19 (1) the composition of which is such that
20 the drug is not generally recognized, among experts qualified
21 by scientific training and experience to evaluate the safety
22 and efficacy of drugs, as safe and effective for use under
23 the conditions prescribed, recommended or suggested in the
24 labeling thereof; or

25 (2) the composition of which is such that

1 the drug, as a result of investigation to determine its
2 safety and efficacy for use under such conditions, has become
3 so recognized, but that has not, otherwise than in such
4 investigations, been used to a material extent or for a
5 material time under such conditions;

6 T. "contaminated with filth" applies to a drug,
7 device or cosmetic not securely protected from dirt, dust
8 and, as far as may be necessary by all reasonable means, from
9 all foreign or injurious contaminations, or a drug, device or
10 cosmetic found to contain dirt, dust, foreign or injurious
11 contamination or infestation;

12 U. "selling of drugs, devices or cosmetics" shall
13 be considered to include the manufacture, production,
14 processing, packing, exposure, offer, possession and holding
15 of any such article for sale and the sale and the supplying
16 or applying of any such article in the conduct of a drug or
17 cosmetic establishment;

18 V. "color additive" means a material that:

19 (1) is a dye, pigment or other substance
20 made by a process of synthesis or similar artifice or
21 extracted, isolated or otherwise derived, with or without
22 intermediate or final change of identity, from a vegetable,
23 mineral, animal or other source; or

24 (2) when added or applied to a drug or
25 cosmetic or to the human body or a part thereof, is capable,

1 alone or through reaction with other substances, of imparting
2 color thereto; except that such term does not include any
3 material that has been or hereafter is exempted under the
4 federal act;

5 W. "federal act" means the Federal Food, Drug and
6 Cosmetic Act;

7 X. "restricted device" means a device for which
8 the sale, distribution or use is lawful only upon the written
9 or oral authorization of a practitioner licensed by law to
10 administer, prescribe or use the device and for which the
11 federal food and drug administration requires special
12 training or skills of the practitioner to use or prescribe.
13 This definition does not include custom devices defined in
14 the federal act and exempt from performance standards or
15 premarket approval requirements under Section 520(b) of the
16 federal act;

17 Y. "prescription device" means a device that,
18 because of its potential for harm, the method of its use or
19 the collateral measures necessary to its use, is not safe
20 except under the supervision of a practitioner licensed in
21 this state to direct the use of such device and for which
22 "adequate directions for use" cannot be prepared, but that
23 bears the label: "Caution: federal law restricts this
24 device to sale by or on the order of a _____", the blank
25 to be filled with the word "physician", "physician

1 assistant", "certified advanced practice chiropractic
2 physician", "doctor of oriental medicine", "dentist",
3 "veterinarian", "euthanasia technician", "certified nurse
4 practitioner", "clinical nurse specialist", "pharmacist",
5 "pharmacist clinician", "certified nurse-midwife" or "dental
6 hygienist", "optometrist" or with the descriptive designation
7 of any other practitioner licensed in this state to use or
8 order the use of the device;

9 Z. "valid practitioner-patient relationship" means
10 a professional relationship, as defined by the practitioner's
11 licensing board, between the practitioner and the patient;

12 AA. "pedigree" means the recorded history of a
13 drug; and

14 BB. "drug order" means an order either directly
15 from a licensed practitioner or the practitioner's agent to
16 the pharmacist, including by means of electronic transmission
17 or indirectly by means of a written order signed by the
18 licensed practitioner or the practitioner's agent, and
19 bearing the name and address of the practitioner and the
20 practitioner's license classification and the name and
21 quantity of the drug or device ordered for use at an
22 inpatient or outpatient facility."

23 SECTION 7. REPEAL.--Section 61-2-10 NMSA 1978 (being
24 Laws 1977, Chapter 30, Section 3, as amended) is repealed._____